Edition:
United States

Bioporto A/S (BIOPOR.CO)

BIOPOR.CO on Copenhagen Stock Exchange

3.28DKK
9:14am EDT
Change (% chg)

kr.0.04 (+1.23%)
Prev Close
kr.3.24
Open
kr.3.24
Day's High
kr.3.30
Day's Low
kr.3.19
Volume
124,674
Avg. Vol
480,258
52-wk High
kr.3.84
52-wk Low
kr.1.40

Latest Key Developments (Source: Significant Developments)

Bioporto Q2 EBIT loss at DKK 8.4 million
Thursday, 10 Aug 2017 02:54am EDT 

Aug 10 (Reuters) - BIOPORTO A/S :‍EBIT FORECAST FOR FINANCIAL YEAR 2017 IS ADJUSTED FROM A LOSS BETWEEN DKK 26-29 MILLION TO A LOSS OF DKK 28 - 35 MILLION​.‍REVENUE IN 2017 IS ADJUSTED FROM DKK 25-28 MILLION TO DKK 26-28 MILLION, EQUIVALENT TO A GROWTH RATE OF 25-35%​.TOTAL REVENUE GREW 42% IN Q2 2017 TO DKK 6.6 MILLION AND TOTALLED DKK 12.4 MILLION FOR FIRST SIX MONTHS OF 2017.SALES GUIDANCE FOR 2017 ADJUSTED AFTER STRONG FIRST HALF OF 2017. EBIT GUIDANCE ADJUSTED.Q2 REVENUE DKK 6.6 ‍​ MILLION VERSUS DKK 4.7 MILLION YEAR AGO.Q2 EBIT LOSS DKK 8.4 MILLION VERSUS LOSS DKK 7.7 MILLION YEAR AGO.  Full Article

Bioporto Q1 EBIT loss widens to DKK 9.3 million
Thursday, 4 May 2017 02:21am EDT 

May 4 (Reuters) - BIOPORTO A/S ::GUIDANCE FOR 2017 MAINTAINED.Q1 EBIT LOSS DKK 9.3 MILLION VERSUS LOSS DKK 5.4 MILLION YEAR AGO.Q1 REVENUE DKK 5.7 MILLION VERSUS DKK 5.2 MILLION YEAR AGO.  Full Article

Bioporto FY EBIT loss widens to DKK 25.0 million
Wednesday, 15 Mar 2017 03:40am EDT 

Bioporto A/S : FY revenue 20.7 million Danish crowns ($3 million) versus 20.4 million crowns year ago . FY EBIT loss 25.0 million crowns versus loss 12.8 million crowns year ago . Expects revenue growth of 20-35 pct in 2017, driven by research sales in US and agreement with Siemens .In 2017 full attention is directed to sales initiatives and targeted efforts to secure successful approval, that are expected to kick-start sales of NGAL test in us in 2018.  Full Article

Bioporto expands its NGAL related patent portfolio
Wednesday, 28 Dec 2016 09:38am EST 

Bioporto A/S : Says expands its NGAL related patent portfolio . Has entered into exclusive license agreement with Trustees of Columbia, University for NGAL patents .Agreement covers several world-wide NGAL patents and applications, with right to sublicense these patents.  Full Article

BioPorto Q2 EBIT loss increases to DKK 7.7 mln
Thursday, 4 Aug 2016 02:57am EDT 

Bioporto A/S : Q2 revenue 4.7 million Danish crowns ($703,382.22) versus 5.8 million crowns year ago . Q2 EBIT loss 7.7 million crowns versus loss 4.0 million crowns year ago . EBIT for full year 2016 is adjusted from a loss of around 16-18 million crowns, to a loss of around 19-21 million crowns . Adjusts its expectations for a turnover in 2016 from around 23-26 million crowns to 23-25, million crowns representing a growth of 13-23 pct .2016 profit after tax is adjusted from a loss of 14.5-16.5 million crowns to a loss of 17-19 million crowns.  Full Article

BioPorto to reapply for FDA approval of NGAL Test
Monday, 4 Jul 2016 05:53am EDT 

BioPorto A/S : Decides to reapply for FDA approval of the NGAL test . Expects to obtain approval within 18-24 months .Financial outlook for 2016 is maintained.  Full Article

Bioporto: FDA rejects application for registration of NGAL Test
Monday, 30 May 2016 01:00am EDT 

Bioporto A/S : The FDA rejects application for the registration og The NGAL Test . Registration application for NGAL Test rejected on grounds that submission does not provide adequate clinical and analytical data to support a reasonable assurance of approval of device . Cannot begin commercialization of NGAL Test for clinical use in US as previously expected, whereas sales for research use continues . As a result of FDA's rejection of application, expectations for 2016 are adjusted . Sees 2016 revenues of around 23 million-26 million Danish crowns ($3.43 million - $3.88 million) (previously around 27-30 million crowns) .Sees 2016 operating loss (EBIT) of 16-18 million crowns (previously a loss of around 11-13 million crowns).  Full Article

Bioporto NGAL Forms patent upheld after EPO ruling
Wednesday, 18 May 2016 08:36am EDT 

Bioporto A/S : Says the company's NGAL Forms patent is upheld after European Patent Office (EPO) ruling .Decision is a first instance decision and can be appealed by the opponent.  Full Article

BioPorto cuts FY 2016 EBIT outlook due to warrants program
Friday, 8 Apr 2016 03:00am EDT 

BioPorto A/S:Adjusts EBIT forecast for FY 2016 due to warrants program for employees.To issue a total of 6,368,696 warrants, exercise price fixed at 4.58 Danish crowns per share.EBIT forecast for FY 2016 is adjusted: from a negative EBIT of around 7 million - 9 million crowns to a negative EBIT of around 11 million - 13 million crowns.  Full Article

BioPorto issues FY 2016 guidance
Wednesday, 16 Mar 2016 03:41am EDT 

BioPorto A/S:In FY 2016, expects to generate revenue of around 27 million – 30 million crowns, equivalent to 30–50 pct growth​.Plans higher investments in long-term growth potential at the expense of the short-term goal of becoming profitable in FY 2016.Says accordingly, in FY 2016 a negative EBIT of around 7 million – 9 million crowns, equivalent to a loss after tax of 5.5 million – 7.5 million crowns, is expected.  Full Article

BRIEF-Bioporto Q2 EBIT loss at DKK 8.4 million

* ‍EBIT FORECAST FOR FINANCIAL YEAR 2017 IS ADJUSTED FROM A LOSS BETWEEN DKK 26-29 MILLION TO A LOSS OF DKK 28 - 35 MILLION​

No consensus analysis data available.